{Economic Information Daily, 30th exclusive} Lizhu Pharmaceutical (01513) is currently up 3.9%, trading at HK$22.8, with approximately 3.76 million shares traded, involving a total value of HK$845.7 million, reaching a high of HK$22.9 and a low of HK$21.5.

   Lizhu Pharmaceutical announced that it has received a supplementary drug application approval notice issued and verified by the National Medical Products Administration, approving the listing of its 11.25mg injectable leuprolide acetate microspheres (3-month formulation).

   The group stated that the injectable leuprolide acetate microspheres are classified as Category B in the "National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug Catalogue," and the 3-month formulation is indicated for premenopausal breast cancer, prostate cancer, and central precocious puberty. As of yesterday, the cumulative direct R&D expenditure for the injectable leuprolide acetate microspheres (3-month formulation) has reached approximately RMB 94.06 million.

   Currently, the Hang Seng Index stands at 24,585, up 61 points or 0.3%, with main board turnover exceeding HK$135.4 billion. The Hang Seng China Enterprises Index is at 8,214, up 35 points or 0.4%. The Hang Seng Tech Index is at 4,246, down 3 points or less than 0.1%. (vs)